계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Simcere Pharma
company
About
Simcere Pharma is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market.
- 1001 - 5000
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- ¥600M
- Industries
- Biotechnology,Manufacturing
- Founded date
- Jan 1, 1995
- Number Of Employee
- 1001 - 5000
- Operating Status
- Active
Founded on 28th March 1995, Simcere swiftly evolved from being a pure distributor of pharmaceutical products to become a leading manufacturer and supplier of drugs in China's rapidly growing pharmaceutical market. Simcere currently operates five GMP-certified manufacturing facilities, two nationwide sales and marketing subsidiaries, a research and development center and manages over 4,000 employees. They are the first Chinese chemical and biological drug company to list on the New York Stock Exchange with IPO proceeds reaching US$ 261 million.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥600M
Simcere Pharma has raised a total of
¥600M
in funding over 2 rounds. Their latest funding was raised on
Jun 4, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 4, 2021 | Series B | ¥600M | 4 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
4
Simcere Pharma is funded by 4 investors.
CITIC Medical Fund
and Tianhui Chuangtou
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series B |
|
|
— | Series B |
Hongcheng Capital
|
— | Series B |
Nanjing Innovation Capital Group
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
